Looped In on Lupus N
Looped In on Lupus Nephritis: American Kidney Fund’s Campaign Focuses on Preventing, Detecting and Managing Lupus Nephritis
February 10, 2022 09:54 ET | American Kidney Fund
ROCKVILLE, Md., Feb. 10, 2022 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announces its Looped In on Lupus Nephritis campaign, which is aimed at improving diagnosis, awareness and...
Logo.png
Lupus Nephritis Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Lupus Pipeline Comprising a Broad Spectrum of Molecular Targets
July 19, 2021 20:10 ET | DelveInsight Business Research LLP
Las Vegas, USA, July 19, 2021 (GLOBE NEWSWIRE) -- Lupus Nephritis Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Lupus Pipeline Comprising a Broad Spectrum of Molecular Targets ...
Equillium_Square_Logo.png
Equillium Reports Third Quarter 2020 Financial Results and Business Highlights
November 10, 2020 16:05 ET | Equillium
LA JOLLA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium_Square_Logo.png
Equillium to Present at Investor Conferences in November 2020
November 10, 2020 08:35 ET | Equillium
LA JOLLA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium_Square_Logo.png
Equillium to Present Data at the 2020 American College of Rheumatology Meeting Demonstrating CD6 Modulation Improves Kidney and Skin Pathology in Preclinical Models of Systemic Lupus Erythematosus
November 04, 2020 08:35 ET | Equillium
Studies further validate ongoing clinical development of itolizumab for the treatment of systemic lupus erythematosus and lupus nephritis LA JOLLA, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) --...
Equillium_Square_Logo.png
Equillium to Present at H.C. Wainwright 22nd Annual Global Investment Conference
September 03, 2020 16:07 ET | Equillium
LA JOLLA, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...
Equillium_Square_Logo.png
Equillium Announces Closing of Public Offering of Common Stock
August 18, 2020 16:05 ET | Equillium
LA JOLLA, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium_Square_Logo.png
Equillium to Present at BTIG Virtual Biotechnology Conference 2020
July 30, 2020 16:07 ET | Equillium
LA JOLLA, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...
Equillium_Square_Logo.png
Equillium to Present at Jefferies Virtual Healthcare Conference
May 21, 2020 16:07 ET | Equillium
LA JOLLA, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...
Equillium_Square_Logo.png
Equillium Reports First Quarter 2020 Financial Results
May 13, 2020 16:07 ET | Equillium
LA JOLLA, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...